Alexander Bruni: Yes. I think that’s tough because getting that data is difficult. But we believe that – look, we look at ourselves as a proxy. And we know we’ve done a really good job in the last quarter taking inventory down, which turned around and helped us generate tremendous cash flow for the quarter. So we know that and we believe that if we’re using ourselves as a proxy, we know we’re thinking they have similar and we’ve probably been more highly focused on moving our inventory out specifically our products to get it to turn. So the short answer here is we don’t have direct visibility to, but we can buy a proxy, look at what we have and believe that across the board, whether it’s the four, five or six distributors that are key distributors to us, we believe they have similar, if not more, than what we would have in stock.
Jonathan Yong: Okay. Thanks.
Operator: Next, we’ll go to John Stansel at JPMorgan.
John Stansel: Good morning. This is Jon on for Lisa. Just a question going back to some of the commentary around sourcing and demand management. It sounds like you’re having positive impacts already, as you said. But I noticed you kind of adjusted the commodity price assumptions in the guidance from kind of stable to improving just to stable. Is there anything more than just like added visibility on kind of the input side that’s changed for you through the quarter? Or kind of what’s driving your cost outlook for the back half? Thank you.
Alexander Bruni: Yes. Thanks, John. Obviously, in our Products division, in particular, we keep a very close eye on commodities and how they impact things. I would say that the update here was just based on a broad look across trends and I think a judgment that it’s probably more stable than stable to improving.
John Stansel: Okay. Great. And then just – I know we had some discussion last quarter around home respiratory, potentially being a little below kind of the average within Patient Direct. How that trend during the quarter? And I guess, are you seeing any changes in patterns there?
Alexander Bruni: Yes. At a high level, in a Patient Direct business, again, just can’t be more pleased that we had double-digit growth overall in that segment. And that’s coming off of some pretty tough comps. So we had double-digit growth on a pro forma basis last year in that segment. The one category coming off of COVID is home respiratory that is still not growing at the rate we wanted to. It has improved sequentially quarter-over-quarter. The other aspect of what we have with the home respiratory is with the Philips recall and NIVs [ph] and other home respiratory products, it has caused us to actually have to spend more capital to get new machines that are qualified. The long-term benefit of that is, though, we’re comfortable that Philips over time is going to get it fixed.
When we get it fixed, we’re going to have – we’re not going to need to spend the capital because those machines will all be refurbished and ready to go. So I guess in the home respiratory, it’s still not where we want it to be. It is improving as the year has progressed. But again, we’ve got to look at the other aspects of it where across all of our categories are two major ones being diabetes and CPAP, both of them growing in the double-digit range. Overall, the total segment growing in double digits. And across the board, whether it’s ostomy and continence, wound care, urology, all those categories continuing to do extremely well in the marketplace.
John Stansel: Appreciate the color.
Operator: We’ll go next to Daniel Grosslight at Citi.
